CN103495172A - Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances - Google Patents

Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances Download PDF

Info

Publication number
CN103495172A
CN103495172A CN201310463559.3A CN201310463559A CN103495172A CN 103495172 A CN103495172 A CN 103495172A CN 201310463559 A CN201310463559 A CN 201310463559A CN 103495172 A CN103495172 A CN 103495172A
Authority
CN
China
Prior art keywords
application
medicine
dependency
opiates
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310463559.3A
Other languages
Chinese (zh)
Inventor
卢正堂
张�荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lu Zhengtang
Zhang Rong
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201310463559.3A priority Critical patent/CN103495172A/en
Publication of CN103495172A publication Critical patent/CN103495172A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances. The medicament is prepared from the following components by weight percent: 2-95% of antipsychotics, 0.001-5% of alpha2 adrenergic agonists, 0-5% of anticholinergic agent, 0-80% of nonopioid analgesic, and 0-10% of benzodiazepine. The pharmaceutical composition disclosed by the invention achieves an ideal effect when the symptoms of a sufferer abusing stimulants such as benzedrine, or abusing the opiates substances in a merging manner are treated; the withdrawal symptom can be rapidly and obviously controlled; the detoxification recovery rate can be up to over 90%.

Description

Treatment amphetamines dependence syndrome and with the medicine of opioid mixed dependence disease
The application is that application number is the division that 201010170021.X, name are called " treatment amphetamines dependence syndrome and with the medicine of opioid mixed dependence disease " application for a patent for invention, and the applying date of original bill is on May 12nd, 2010.
Technical field
The present invention relates to the Medicines technical field, specifically a kind of composition of medicine for the treatment of amphetamines dependence syndrome, amphetamines and opioid mixed dependence disease.
Background technology
At present, the drug dependence problem is comparatively serious, and the material of abuse has: the analeptic such as amfetamine (being commonly called as: methamphetamine hydrochloride, head-shaking pill, KET etc.), opioid (as: morphine, heroin, tinctura opii, opium etc.) etc.The medicine that some treatments are arranged on market, but curative effect is all undesirable, and all can only treat a certain Abused drug dependence.But the problem ubiquity of multiple medicines or many substance abuses, for example: in China, the situation of amphetamines and opioid mixed dependence was clinical often visible in recent years, not only do not treat the medicine that amphetamines and opioid rely on, be exactly that single therapy amphetamines or opioid rely on, all not undesirable containing the curative effect of medication of opioid simultaneously.
Summary of the invention
The purpose of this invention is to provide a kind of non-opium composition of medicine that is used for the treatment of amphetamines dependence syndrome, amphetamines and opioid mixed dependence disease.
The object of the present invention is achieved like this: by by antipsychotic drug, α 23 adrenergic receptor agonists or and anticholinergic agent or and nonopioid analgesic or and benzene phenodiazine the class medicine is combined and is provided solution.
The antipsychotic drug that the combination medicine for the treatment of amphetamines dependence syndrome of the present invention, amphetamines and opioid mixed dependence disease is 2-95% by percentage by weight and the α of 0.001-5% 23 adrenergic receptor agonists forms.
Also can be respectively in aforementioned pharmaceutical compositions or add the anticholinergic agent that percentage by weight is 0-5%, the nonopioid analgesic of 0-80% and the benzene phenodiazine of 0-10% simultaneously
Figure BDA0000392167530000012
the class medicine.
In above-mentioned medicine components:
Antipsychotic drug can be one or more in following medicine: olanzapine, penfluridol, paroxetine, risperidone, Aripiprazole, trifluoperazine, mirtazapine, perphenazine, fluphenazine.
α 23 adrenergic receptor agonists can be one or more in following medicine: BA-168, chlorine vinegar amine miaow, clonidine, lofexidine.
Anticholinergic agent can be one or more in following medicine: Semen daturae, Anisodamine, scopolamine, atropine, benzetropine, probanthine, benactyzine, benzoglycolic acid quinine ester, benzhexol, diphenhydramine, Anisodine, Pirenzepine, propyl group dibenzoyl choline chlormethine, kemadrin, K toxin.
Nonopioid analgesic can be one or more in following medicine: tetrahydropalmatine, tramadol, benzoxazocine, Dicentrine, rotundine, four nitrogen Zhuos, tetrahydropalmatine.
The benzene phenodiazine the class medicine can be one or more in following medicine: stable, estazolam, nitrodiazepam, fludiazepam, flunitrazepan, flurazepam, oxazepan, L0, clonazepam, chlorine nitrogen
Figure BDA0000392167530000022
alprazolam, etizolam, Midazolam, Convertal etc.
Combine with any suitable excipient with prescription of the present invention and can make the above dosage form of any pharmaceutics.
Analeptic such as abuse amfetamine etc., photis, the auditory hallucination that the patient occurs, suspect, many mental symptoms such as fear, delusion of persecution, anxiety, pessimism, suicide, need the application high-titer, hang down the antipsychotic medications of side effect.
The analeptic such as abuse amfetamine, the patient there will be blood pressure to increase, and causes the internal organs ischemia, causes the diseases such as cerebral palsy, myocardial ischemia, needs application α 23 adrenergic receptor agonists carries out Treatment of Hypertension, can treat the refraining opium type material symptom that merges the misuser simultaneously.
The side effect such as vertebral body is outward can occur in the antipsychotic drug of high-titer, need application anticholinergic agent antagonism.
Most of drug abuse person often merges the abuse opioid, and more serious stomachache, extremities joint pain and whole body pain etc. are arranged in opioid dependent's withdrawal symptom, needs the treatment of application nonopioid analgesic.
Most of drug abuse person often merges the medicines such as abuse triazolam, and meeting epilepsy between During The Withdrawal Period, need application benzene phenodiazine
Figure BDA0000392167530000023
the class Drug therapy.
Pharmaceutical composition of the present invention is for the abuse analeptic such as amfetamine or when merging above-mentioned symptom that the patient of abuse opioid occurs and being treated, reached comparatively ideal effect, can control rapidly, significantly withdrawal symptom, the detoxification cure rate reaches more than 90%.
The each oral 1-4 grain of tablet, capsule and pill, the each oral 10-40 milliliter of unguentum and syrup, spray sprays the 10-40 milliliter in abdomen, the external of skin of back place at every turn, and every kind of dosage form is all used 1-2 time every day, within 7-10 days, is a course for the treatment of.
The clinical experiment visual report
One, materials and methods
(1) object of observation
20 routine amphetamines dependents, 20 routine amphetamines and opioid mixed dependence person are observed in this checking, and inclusion criteria is as follows:
1, the clinical criteria that meets Ministry of Public Health " amphetamines relies on the diagnoses and treatment guideline "; Merge the clinical criteria that opioid mixed dependence person meets Ministry of Public Health " opioid drug relies on the diagnoses and treatment guideline ";
2, get rid of mental disorder, the heart, liver, kidney disease and other serious physical diseases;
3, during the treatment, nothing continues to use analeptic or the opioids such as amphetamine.
(2) research method
All cases are only used pharmaceutical composition of the present invention for medicine, tightly completely cut off analeptic or the opioids such as amphetamine.
1, efficacy assessment standard and method
This research is strictly evaluated by related standards and the method for Ministry of Public Health regulation.According to " withdrawal symptom is observed table day by day " (OWS scale), whole day nursing observation, and shown effect to patient's withdrawal symptom, the record of marking day by day by the special messenger 15 to 16 o'clock every days.After observing medication, within 10th, stop.
2, toxicity untoward reaction evaluation criteria and method
(1) according to " new drug untoward reaction observe scale " whole day nursing observation, and be responsible for medication person's the untoward reaction record of marking day by day by the special messenger 15 to 16 o'clock every days.After observing medication, within 10th, stop.
(2) Examine observe: all patient is carried out to general vital sign observation every day before treatment starts and during treatment, record faithfully in progress note.
3, detoxification standard
(1) stop using pharmaceutical composition of the present invention 10 days courses for the treatment of to the;
(2) the acute withdrawal symptom is eliminated substantially;
(3) merge the 8th day course for the treatment of of opioid dependent, naloxone urges addiction experiment (0.4 milligram of intramuscular injection) feminine gender, urine morphine to detect negative.
4, medication
Supervise then and there and take medicine one by one by the medical worker.Warm water takes, and dosage, according to the abuse time of experimenter's amphetamines or opioid, the use amount of nearly a week, reaches withdrawal symptom and controls degree and determine, and directs consumption concretely and is:
Figure BDA0000392167530000031
Figure BDA0000392167530000041
Two, observed result
(1) to controlling the observation of curative effect of withdrawal symptom
1, to the control rate of withdrawal symptom
Administration time is apart from the last time average of taking drugs: the amphetamines dependent is 8.6 hours, and amphetamines and opioid mixed dependence person are 11.9 hours.
Before administration, obvious withdrawal symptom all appears in all cases, and the scoring mean: the amphetamines dependent is 50.2 ± 5.8; Amphetamines and opioid mixed dependence person are 52.3 ± 5.6.
After taking pharmaceutical composition of the present invention, withdrawal symptom is all obviously alleviated (referring to table 1).
The scoring of table 1. withdrawal symptom changes the mean table day by day
Figure BDA0000392167530000042
Annotate: variance analysis, relatively front with treatment
From table 1: pharmaceutical composition administration of the present invention same day, withdrawal symptom is obviously controlled, after medication before withdrawal symptom scoring every day and medication relatively, difference has significance.
2, the occurrence rate of withdrawal symptom
During treating, pharmaceutical composition of the present invention can be controlled withdrawal symptom obviously, effectively, and for strict this medicine of estimating, to eliminating or alleviate the difference on effect of different withdrawal symptoms, we observe and add up the occurrence rate of various withdrawal symptoms:
Table 2. withdrawal symptom occurrence rate (n=20)
Figure BDA0000392167530000051
From table 2: the amphetamines dependent, except 3 examples occur anxiety symptom, other symptoms all can be controlled fully.
Amphetamines and opioid mixed dependence person, except anxiety, extremities joint pain, yawn and fatigue and weak control are undesirable, other symptoms all can be fully or basic controlling, and these several symptoms all belong to the addiction initial stage, a lighter withdrawal symptom, take pharmaceutical composition of the present invention to the patient immediately, these several withdrawal symptoms all are effectively controlled, and diarrhoea, vomiting, paroxysmal tic etc. come across to be sent out the addiction middle and late stage stage, comparatively serious withdrawal symptom and also can not occur.
(2) toxicity and untoward reaction
During treating, untoward reaction situation statistics is as follows:
Table 3. untoward reaction occurrence rate (n=20)
Figure BDA0000392167530000061
Table 4. untoward reaction scoring changes the mean table day by day
Figure BDA0000392167530000063
From table 3,4: the untoward reaction main manifestations is dizzy, weak.Untoward reaction and dosage are proportionate, and within first 3 days, dosage is larger, and the side reaction scoring is also higher, and along with the minimizing of dosage, side reaction also alleviates gradually, after drug withdrawal, disappear fully.
Three, conclusion
(1) pharmaceutical composition control withdrawal symptom effect of the present invention is remarkable
From table 1,2: as long as dosage holds water, all medication persons' withdrawal symptom all obviously being controlled without exception.
(2) pharmaceutical composition control withdrawal symptom of the present invention effect is rapid
In actual observation, medication is about 30 minutes, and withdrawal symptom is controlled.
(3) side effect of pharmaceutical composition of the present invention is less
From table 3,4: the untoward reaction of this medicine is less, and, along with the minimizing of dosage, side reaction also alleviates gradually, after drug withdrawal, disappears fully.
(4) pharmaceutical composition of the present invention is taken safety
This medicine is not containing any poisonous substances, and all the components is all the Chinese medicine and western medicine kind that state-promulgated pharmacopoeia is recorded, safer.
The specific embodiment
Below in conjunction with embodiment, the invention will be further described:
Embodiment 1:
The percentage by weight of medicine components is: 92% olanzapine, 3% chlorine vinegar amine miaow, 5% diphenhydramine, by after the adjuvants such as starch, Pulvis Talci and said medicine raw material blending, by the method for prior art, make capsule (200 milligrams every).
Embodiment 2:
The percentage by weight of medicine components is: 85% mirtazapine, 2% lofexidine, 5% scopolamine, 8% flunitrazepan, by after the adjuvants such as starch, Pulvis Talci and said medicine raw material blending, by the method for prior art, make tablet (200 milligrams every).
Embodiment 3:
The percentage by weight of medicine components: 90% Aripiprazole, 5% BA-168,5% benzhexol, will after the adjuvants such as starch, Pulvis Talci and said medicine raw material blending, by the method for prior art, make capsule (200 milligrams every).
Embodiment 4:
The percentage by weight of medicine components: 32% Paroxetine, 3% BA-168,5% Radix Anisodi Acutanguli, 60% tramadol, will make pill (200 milligrams every) by the method for prior art after the adjuvants such as starch, Pulvis Talci and said medicine raw material blending.
Embodiment 5:
The percentage by weight of medicine components: 95% penfluridol, 5% clonidine, will after the adjuvants such as 95% ethanol, laurocapram and said medicine raw material blending, by the method for prior art, make spray.
Embodiment 6:
The percentage by weight of medicine components: 90% risperidone, 5% BA-168,5% Semen daturae, will after the adjuvants such as syrup and said medicine raw material blending, by the method for prior art, make unguentum.
Embodiment 7:
The percentage by weight of medicine components: 84% fluphenazine, 5% lofexidine, 3% atropine, 8% fludiazepam, by after the adjuvants such as starch, Pulvis Talci and said medicine raw material blending, by the method for prior art, make capsule (200 milligrams every).
Embodiment 8:
The percentage by weight of medicine components: 74% trifluoperazine, 5% chlorine vinegar amine miaow, 3% benzetropine, 8% rotundine, 10% chlorine nitrogen
Figure BDA0000392167530000081
to after the adjuvants such as monosaccharide and said medicine raw material blending, by the method for prior art, make syrup.
Embodiment 9:
The percentage by weight of medicine components: 10% perphenazine, 2% BA-168,80% tetrahydropalmatine, 8% clonazepam, by after the adjuvants such as starch, Pulvis Talci and said medicine raw material blending, by the method for prior art, make tablet (200 milligrams every).
Embodiment 10:
The percentage by weight of medicine components: 85% haloperidol, 5% chlorine vinegar amine miaow, 10% estazolam, will after the adjuvants such as 95% ethanol, laurocapram and said medicine raw material blending, by the method for prior art, make spray.

Claims (6)

  1. A pharmaceutical composition preparation treatment amphetamines dependence syndrome and with the medicine of opioid mixed dependence disease in application, it is characterized in that:
    The antipsychotic drug that described pharmaceutical composition is 2-95% by percentage by weight, the α of 0.001-5% 2the benzene phenodiazine of the anticholinergic agent of 3 adrenergic receptor agonists, 0-5%, the nonopioid analgesic of 0-80%, 0-10% the class ingredients.
  2. 2. application as claimed in claim 1 is characterized in that:
    Described antipsychotic drug is one or more in olanzapine, penfluridol, paroxetine, risperidone, Aripiprazole, trifluoperazine, mirtazapine, perphenazine, fluphenazine.
  3. 3. application as claimed in claim 1 or 2 is characterized in that:
    Described α 23 adrenergic receptor agonists is one or more in BA-168, chlorine vinegar amine miaow, clonidine, lofexidine.
  4. 4. application as described as one of claim 1-3 is characterized in that:
    Described anticholinergic agent is one or more in Semen daturae, Anisodamine, scopolamine, atropine, benzetropine, probanthine, benactyzine, benzoglycolic acid quinine ester, benzhexol, diphenhydramine, Anisodine, Pirenzepine, propyl group dibenzoyl choline chlormethine, kemadrin, K toxin.
  5. 5. application as described as one of claim 1-4 is characterized in that:
    Described nonopioid analgesic is one or more in tetrahydropalmatine, tramadol, benzoxazocine, Dicentrine, rotundine, four nitrogen Zhuos, tetrahydropalmatine.
  6. 6. application as described as one of claim 1-5 is characterized in that:
    Described benzene phenodiazine
    Figure FDA0000392167520000012
    the class medicine be stabilize, estazolam, nitrodiazepam, fludiazepam, flunitrazepan, flurazepam, oxazepan, L0, clonazepam, chlorine nitrogen
    Figure FDA0000392167520000013
    , one or more in alprazolam, etizolam, Midazolam, Convertal.
CN201310463559.3A 2010-05-12 2010-05-12 Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances Pending CN103495172A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310463559.3A CN103495172A (en) 2010-05-12 2010-05-12 Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310463559.3A CN103495172A (en) 2010-05-12 2010-05-12 Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201010170021.XA Division CN101829328B (en) 2010-05-12 2010-05-12 Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome

Publications (1)

Publication Number Publication Date
CN103495172A true CN103495172A (en) 2014-01-08

Family

ID=49860487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310463559.3A Pending CN103495172A (en) 2010-05-12 2010-05-12 Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances

Country Status (1)

Country Link
CN (1) CN103495172A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112245435A (en) * 2020-09-28 2021-01-22 湖南农业大学 Composition for relieving gelsemium elegans poisoning and application thereof
CN112494486A (en) * 2020-12-07 2021-03-16 深圳善康医疗健康产业有限公司 Pharmaceutical composition for relieving or eliminating opium withdrawal syndrome and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146549A1 (en) * 2006-12-18 2008-06-19 Coleman Peter R Accelerated opiate dependence detoxification process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146549A1 (en) * 2006-12-18 2008-06-19 Coleman Peter R Accelerated opiate dependence detoxification process

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
李亚萍: "浅议戒毒药物", 《医疗装备》, 31 July 2008 (2008-07-31) *
江海峰等: "***类***滥用的治疗研究进展", 《中国药物依赖性杂志》, vol. 17, no. 4, 30 April 2008 (2008-04-30) *
马丽霞等: "戒毒药物研究进展", 《第二届中国古代毒物学史研讨会论文集》, 31 December 2005 (2005-12-31) *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112245435A (en) * 2020-09-28 2021-01-22 湖南农业大学 Composition for relieving gelsemium elegans poisoning and application thereof
CN112245435B (en) * 2020-09-28 2023-06-13 湖南农业大学 Composition for rescuing gelsemium intoxication and application thereof
CN112494486A (en) * 2020-12-07 2021-03-16 深圳善康医疗健康产业有限公司 Pharmaceutical composition for relieving or eliminating opium withdrawal syndrome and application thereof
CN112494486B (en) * 2020-12-07 2022-01-21 深圳善康医疗健康产业有限公司 Pharmaceutical composition for relieving or eliminating opium withdrawal syndrome and application thereof
WO2022120745A1 (en) 2020-12-07 2022-06-16 深圳善康医疗健康产业有限公司 Medicine for relieving or eliminating protracted opioid abstinence syndrome and preparation method therefor

Similar Documents

Publication Publication Date Title
TWI355936B (en) Uses of palonosetron hydrochloride
White et al. Open-label dose-finding trial of buprenorphine implants (Probuphine)® for treatment of heroin dependence
CN102143687A (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
CN107213149A (en) Purposes of the artemisinin derivatives in treatment or auxiliary treatment AITD medicine is prepared
Everett et al. The pharmacology of medieval sedatives: The “Great Rest” of the Antidotarium nicolai
CN101829328B (en) Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome
US20220071989A1 (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
CN103495172A (en) Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances
CN112569237B (en) Application of combination or compound of imatinib and derivatives thereof and nicotine or analogues thereof in preventing and treating nicotine addiction and relapse
EP2830605A1 (en) A combination medicament comprising phenylephrine and paracetamol
JP6181754B2 (en) Condensed benzazepine for the treatment of Tourette syndrome
CN101375954B (en) Medicament composition, preparation method thereof and use
AU2013211546B1 (en) A Medicament
Deslandes et al. Rapid medicines management for healthcare professionals
AU2011202637A1 (en) Composition and methods for treating myelodysplastic syndrome
CN107281183B (en) Analgesic composition
Dreyer Pharmacology for nurses and other health workers
Winner et al. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults
CN1259974C (en) Drug giving-up medicine made-up by non-thebaica medicines
Cappello Medication-Assisted Treatment (MAT) in the Emergency Department
Kiran et al. POST-MARKETING SURVEILLANCE STUDY TO EVALUATE THE EFFICACY AND SAFETY FOR THE COMBINATION OF PARACETAMOL, PHENYLEPHRINE AND CHLORPHENIRAMINE MALEATE IN PAEDIATRIC PATIENTS OF COMMON COLD
CN114392269A (en) Antiallergic injection composition and preparation method and application thereof
Hichiya et al. Evaluation of oral antidepressant drugs for adaptation to the simple suspension method
CN103536864B (en) Chinese herbal medicine drug treatment composition
CN106660937A (en) Dosage of dasotraline and method for treatment of adhd

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ZHANG RONG

Effective date: 20141014

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20141014

Address after: 650200, Kunming, Yunnan province China World Trade Center Center North million impression 4 units 2, No. 301 Zhang Rongzhuan

Applicant after: Lu Zhengtang

Applicant after: Zhang Rong

Address before: 650200, Kunming, Yunnan province China World Trade Center Center North million impression 4 units 2, No. 301 Zhang Rongzhuan

Applicant before: Lu Zhengtang

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140108